Cargando…

Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer

Cancer-associated fibroblasts (CAFs) are a major contributor to tumor stromal crosstalk in the tumor microenvironment (TME) and boost tumor progression by promoting angiogenesis and lymphangiogenesis. This study aimed to identify prognostic genes associated with CAFs that lead to high morbidity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Songwei, Xu, Yi, Dai, Zhu, Yin, Han, Zhang, Ke, Shen, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304893/
https://www.ncbi.nlm.nih.gov/pubmed/35874760
http://dx.doi.org/10.3389/fimmu.2022.951582
_version_ 1784752193828552704
author Feng, Songwei
Xu, Yi
Dai, Zhu
Yin, Han
Zhang, Ke
Shen, Yang
author_facet Feng, Songwei
Xu, Yi
Dai, Zhu
Yin, Han
Zhang, Ke
Shen, Yang
author_sort Feng, Songwei
collection PubMed
description Cancer-associated fibroblasts (CAFs) are a major contributor to tumor stromal crosstalk in the tumor microenvironment (TME) and boost tumor progression by promoting angiogenesis and lymphangiogenesis. This study aimed to identify prognostic genes associated with CAFs that lead to high morbidity and mortality in ovarian cancer (OC) patients. We performed bioinformatics analysis in 16 multicenter studies (2,742 patients) and identified CAF-associated hub genes using the weighted gene co-expression network analysis (WGCNA). A machine learning methodology was used to identify COL16A1, COL5A2, GREM1, LUM, SRPX, and TIMP3 and construct a prognostic signature. Subsequently, a series of bioinformatics algorithms indicated risk stratification based on the above signature, suggesting that high-risk patients have a worse prognosis, weaker immune response, and lower tumor mutational burden (TMB) status but may be more sensitive to routine chemotherapeutic agents. Finally, we characterized prognostic markers using cell lines, immunohistochemistry, and single-cell sequencing. In conclusion, these results suggest that the CAF-related signature may be a novel pretreatment guide for anti-CAFs, and prognostic markers in CAFs may be potential therapeutic targets to inhibit OC progression.
format Online
Article
Text
id pubmed-9304893
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93048932022-07-23 Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer Feng, Songwei Xu, Yi Dai, Zhu Yin, Han Zhang, Ke Shen, Yang Front Immunol Immunology Cancer-associated fibroblasts (CAFs) are a major contributor to tumor stromal crosstalk in the tumor microenvironment (TME) and boost tumor progression by promoting angiogenesis and lymphangiogenesis. This study aimed to identify prognostic genes associated with CAFs that lead to high morbidity and mortality in ovarian cancer (OC) patients. We performed bioinformatics analysis in 16 multicenter studies (2,742 patients) and identified CAF-associated hub genes using the weighted gene co-expression network analysis (WGCNA). A machine learning methodology was used to identify COL16A1, COL5A2, GREM1, LUM, SRPX, and TIMP3 and construct a prognostic signature. Subsequently, a series of bioinformatics algorithms indicated risk stratification based on the above signature, suggesting that high-risk patients have a worse prognosis, weaker immune response, and lower tumor mutational burden (TMB) status but may be more sensitive to routine chemotherapeutic agents. Finally, we characterized prognostic markers using cell lines, immunohistochemistry, and single-cell sequencing. In conclusion, these results suggest that the CAF-related signature may be a novel pretreatment guide for anti-CAFs, and prognostic markers in CAFs may be potential therapeutic targets to inhibit OC progression. Frontiers Media S.A. 2022-07-08 /pmc/articles/PMC9304893/ /pubmed/35874760 http://dx.doi.org/10.3389/fimmu.2022.951582 Text en Copyright © 2022 Feng, Xu, Dai, Yin, Zhang and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Feng, Songwei
Xu, Yi
Dai, Zhu
Yin, Han
Zhang, Ke
Shen, Yang
Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer
title Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer
title_full Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer
title_fullStr Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer
title_full_unstemmed Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer
title_short Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer
title_sort integrative analysis from multicenter studies identifies a wgcna-derived cancer-associated fibroblast signature for ovarian cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304893/
https://www.ncbi.nlm.nih.gov/pubmed/35874760
http://dx.doi.org/10.3389/fimmu.2022.951582
work_keys_str_mv AT fengsongwei integrativeanalysisfrommulticenterstudiesidentifiesawgcnaderivedcancerassociatedfibroblastsignatureforovariancancer
AT xuyi integrativeanalysisfrommulticenterstudiesidentifiesawgcnaderivedcancerassociatedfibroblastsignatureforovariancancer
AT daizhu integrativeanalysisfrommulticenterstudiesidentifiesawgcnaderivedcancerassociatedfibroblastsignatureforovariancancer
AT yinhan integrativeanalysisfrommulticenterstudiesidentifiesawgcnaderivedcancerassociatedfibroblastsignatureforovariancancer
AT zhangke integrativeanalysisfrommulticenterstudiesidentifiesawgcnaderivedcancerassociatedfibroblastsignatureforovariancancer
AT shenyang integrativeanalysisfrommulticenterstudiesidentifiesawgcnaderivedcancerassociatedfibroblastsignatureforovariancancer